Relevance of theoretical molecular descriptors in quantitative structure-activity relationship analysis of alpha1-adrenergic receptor antagonists.
暂无分享,去创建一个
M. Karelson | M. Menziani | P. D. De Benedetti | P G De Benedetti | M C Menziani | M Montorsi | M Karelson | M. Montorsi
[1] L B Kier,et al. Use of molecular negentropy to encode structure governing biological activity. , 1980, Journal of pharmaceutical sciences.
[2] Paul R. Yarnold,et al. Reading and Understanding Multivariate Statistics , 1995 .
[3] M. Cocchi,et al. Conformational analysis, molecular modeling and quantitative structure-activity relationship studies of 2,4-diamino-6,7-dimethoxy-2-substituted quinazoline α1-adrenergic antagonists , 1991 .
[4] M. Cocchi,et al. Theoretical quantitative size and shape activity and selectivity analyses of 5-HT1A serotonin and α1-adrenergic receptor ligands , 1994 .
[5] M. Karelson,et al. Theoretical descriptors in quantitative structure-affinity and selectivity relationship study of potent N4-substituted arylpiperazine 5-HT1A receptor antagonists. , 1998, Bioorganic & medicinal chemistry.
[6] M. Karelson,et al. Quantum-Chemical Descriptors in QSAR/QSPR Studies. , 1996, Chemical reviews.
[7] K. Minneman,et al. Subtypes of α1adrenoceptors in rat blood vessels , 1990 .
[8] Peter C. Jurs,et al. Descriptions of molecular shape applied in studies of structure/activity and structure/property relationships , 1987 .
[9] M. Karelson,et al. Correlation of Boiling Points with Molecular Structure. 1. A Training Set of 298 Diverse Organics and a Test Set of 9 Simple Inorganics , 1996 .
[10] J. Hieble,et al. Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. , 1995, Journal of medicinal chemistry.
[11] J. Blagg,et al. Pharmacological options in the treatment of benign prostatic hyperplasia. , 1997, Journal of medicinal chemistry.
[12] Eamonn F. Healy,et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .
[13] M. Cocchi,et al. Molecular modelling and quantitative structure-activity relationship analysis using theoretical descriptors of 1,4-benzodioxan (WB-4101) related compounds α1-adrenergic antagonists , 1992 .
[14] M. Cocchi,et al. Computer modeling of size and shape descriptors of alpha 1-adrenergic receptor antagonists and quantitative structure-affinity/selectivity relationships. , 1998, Methods.
[15] M. Cocchi,et al. Conformational analysis and theoretical quantitative size and shape-affinity relationships of N4-protonated N1-arylpiperazine 5-HT1A serotoninergic ligands , 1997 .
[16] Marina Cocchi,et al. Use of the Supermolecule Approach to Derive Molecular Similarity Descriptors for QSAR Analysis , 1998 .
[17] Gerhard Klebe,et al. What Can We Learn from Molecular Recognition in Protein–Ligand Complexes for the Design of New Drugs? , 1996 .
[18] T. Langer,et al. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 1. Mapping the central 5-HT3 receptor binding site by arylpiperazine derivatives. , 1998, Journal of medicinal chemistry.
[19] M. Karelson,et al. QSPR: the correlation and quantitative prediction of chemical and physical properties from structure , 1995 .
[20] P. Jurs,et al. Development and use of charged partial surface area structural descriptors in computer-assisted quantitative structure-property relationship studies , 1990 .